Primary customers include healthcare providers and institutions treating patients with serious hematologic disorders, particularly those with unmet medical needs in red blood cell and iron regulation.The company operates a biotechnology business model, investing in research and development to bring novel therapies through clinical trials toward regulatory approval and future commercialization.What is the market context for this transaction? The transaction occurred at a weighted average price of $78.69 per ...